PharmaSGP Holding (XTRA:PSG) - Share price, News & Analysis

PSG fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	2/6
Financial Health	5/6
Dividends	0/6

PSG Stock Overview

PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany.

Rewards

Trading at 59.8% below our estimate of its fair value

Earnings are forecast to grow 11.63% per year

Risk Analysis

High level of non-cash earnings

PharmaSGP Holding Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PharmaSGP Holding
Historical stock prices
Current Share Price	€24.20
52 Week High	€27.00
52 Week Low	€18.05
Beta	0
1 Month Change	3.42%
3 Month Change	6.14%
1 Year Change	7.08%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-29.85%

Recent News & Updates

Dec 02

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

It's been a good week for PharmaSGP Holding SE ( ETR:PSG ) shareholders, because the company has just released its...

Shareholder Returns

	PSG	DE Pharmaceuticals	DE Market
7D	-0.4%	3.8%	2.2%
1Y	7.1%	21.7%	-11.9%

Return vs Industry: PSG underperformed the German Pharmaceuticals industry which returned 21.7% over the past year.

Return vs Market: PSG exceeded the German Market which returned -11.9% over the past year.

Price Volatility

Is PSG's price volatile compared to industry and market?
PSG volatility
PSG Average Weekly Movement	4.4%
Pharmaceuticals Industry Average Movement	6.5%
Market Average Movement	6.2%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	3.4%

Stable Share Price: PSG is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: PSG's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2012	66	Natalie Weigand	https://pharmasgp.com

PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company’s pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments.

PharmaSGP Holding Fundamentals Summary

How do PharmaSGP Holding's earnings and revenue compare to its market cap?
PSG fundamental statistics
Market Cap	€290.40m
Earnings (TTM)	€10.69m
Revenue (TTM)	€65.34m

27.2x

P/E Ratio

4.4x

P/S Ratio

Is PSG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
PSG income statement (TTM)
Revenue	€65.34m
Cost of Revenue	€6.49m
Gross Profit	€58.86m
Other Expenses	€48.17m
Earnings	€10.69m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	0.89
Gross Margin	90.07%
Net Profit Margin	16.36%
Debt/Equity Ratio	0%

How did PSG perform over the long term?

See historical performance and comparison

Valuation

Is PharmaSGP Holding undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: PSG (€24.2) is trading below our estimate of fair value (€60.23)

Significantly Below Fair Value: PSG is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: PSG is poor value based on its Price-To-Earnings Ratio (27.2x) compared to the German Pharmaceuticals industry average (24.3x).

PE vs Market: PSG is poor value based on its Price-To-Earnings Ratio (27.2x) compared to the German market (17.5x).

Price to Earnings Growth Ratio

PEG Ratio: PSG is poor value based on its PEG Ratio (2.3x)

Price to Book Ratio

PB vs Industry: PSG is overvalued based on its Price-To-Book Ratio (13.1x) compared to the DE Pharmaceuticals industry average (2.6x).

Future Growth

How is PharmaSGP Holding forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

11.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PSG's forecast earnings growth (11.6% per year) is above the savings rate (-0.05%).

Earnings vs Market: PSG's earnings (11.6% per year) are forecast to grow faster than the German market (8.1% per year).

High Growth Earnings: PSG's earnings are forecast to grow, but not significantly.

Revenue vs Market: PSG's revenue (9.8% per year) is forecast to grow faster than the German market (4.7% per year).

High Growth Revenue: PSG's revenue (9.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PSG's Return on Equity is forecast to be very high in 3 years time (42.7%).

Past Performance

How has PharmaSGP Holding performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-11.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PSG has a high level of non-cash earnings.

Growing Profit Margin: PSG's current net profit margins (16.4%) are lower than last year (16.8%).

Past Earnings Growth Analysis

Earnings Trend: PSG's earnings have declined by 11.1% per year over the past 5 years.

Accelerating Growth: PSG's earnings growth over the past year (0.5%) exceeds its 5-year average (-11.1% per year).

Earnings vs Industry: PSG earnings growth over the past year (0.5%) underperformed the Pharmaceuticals industry 17.7%.

Return on Equity

High ROE: PSG's Return on Equity (48.2%) is considered outstanding.

Financial Health

How is PharmaSGP Holding's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: PSG's short term assets (€32.5M) do not cover its short term liabilities (€92.7M).

Long Term Liabilities: PSG's short term assets (€32.5M) exceed its long term liabilities (€334.0K).

Debt to Equity History and Analysis

Debt Level: PSG is debt free.

Reducing Debt: PSG had no debt 5 years ago.

Debt Coverage: PSG has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: PSG has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Dividend

What is PharmaSGP Holding current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

2.10%

Forecast Dividend Yield

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PSG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PSG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PSG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PSG's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PSG has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average board tenure

CEO

Natalie Weigand (40 yo)

1.92yrs

Tenure

€272,000

Compensation

Ms. Natalie Weigand is Chief Executive Officer of PharmaSGP Holding SE since June 2020 and also serves as its Member of Management Board. She joined the FUTRUE Group as the leader of strategic marketing in...

CEO Compensation Analysis

Compensation vs Market: Natalie's total compensation ($USD291.41K) is below average for companies of similar size in the German market ($USD890.29K).

Compensation vs Earnings: Natalie's compensation has been consistent with company performance over the past year.

Board Members

Experienced Board: PSG's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/28 00:00
End of Day Share Price	2022/05/27 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31